Clinical Trial Update: A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of Mycobacterium w and docetaxel in metastatic castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Mycobacterium w (Mycobacterium w)

Snippet

Sponsor: Cadila Pharnmaceuticals | Conditions: Hormone Refractory Prostate Cancer | Phase 2 | Status: TERMINATED